NeuroSigma.png
Clinical Trial of NeuroSigma’s Monarch eTNS System for ADHD at King’s College London Completes Enrollment
13 janv. 2025 09h00 HE | NeuroSigma, Inc.
ATTENS (ADHD trial of external trigeminal nerve stimulation) Project, led by Professor Katya Rubia at the Institute of Psychiatry, Psychology & Neuroscience is a multicentre, double-blind,...
Cingulate_Logo_400x400_twitter.jpg
Final Study Completed for Cingulate’s Lead Asset CTx-1301
07 janv. 2025 07h30 HE | Cingulate Inc.
No Serious Adverse Events ReportedSubmission of New Drug Application Targeted for Mid 2025 KANSAS CITY, Kan., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical...
Cingulate_Logo_400x400_twitter.jpg
Cingulate Completes Financing Transaction for Net Proceeds of $5,000,000
23 déc. 2024 07h30 HE | Cingulate Inc.
KANSAS CITY, Kan., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
NeuroSigma.png
New Clinical Trial of eTNS for Pediatric ADHD to Commence at Denmark’s Center for Evidence-Based Psychiatry
11 déc. 2024 09h00 HE | NeuroSigma, Inc.
LOS ANGELES, Dec. 11, 2024 (GLOBE NEWSWIRE) -- NeuroSigma, Inc., a Los Angeles-based bioelectronics company, announced today that the Center for Evidence-Based Psychiatry (CEBP) in Denmark has...
BBRF Webinar
ADHD: What You Need to Know
19 nov. 2024 10h00 HE | Brain & Behavior Research Foundation
New York, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Attention-Deficit Hyperactivity Disorder (ADHD) is one of the most common mental health disorders of childhood. On Wednesday, December 4, 2024, at 7 p.m....
CHADD.png
Annual International Conference on ADHD Hosted by CHADD, ADDA and ACO Provides Trusted Information, Guidance and Support to the ADHD Community The Annual International Conference on ADHD 2024, hosted by CHADD, ADDA and ACO, will be held November 14 through 16 in Anaheim, California.
Cingulate_Logo_400x400_twitter.jpg
Cingulate Reports Third Quarter 2024 Financial Results Reflecting $19.5 Million Increase in Working Capital to Advance ADHD Drug to Market
07 nov. 2024 07h30 HE | Cingulate Inc.
KANSAS CITY, Kan., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform...
Praxis_logo 2022 copy.png
Praxis Bioresearch Obtains FDA Clearance On the IND Application for Its Lead Candidate PRX-P4-003 In Alzheimer’s Disease Apathy
29 oct. 2024 07h48 HE | Praxis Bioresearch, Inc.
LOS ANGELES, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Praxis Bioresearch reports that the United States Food and Drug Administration (FDA) has cleared the investigational new drug (IND) application for...
CHADD.png
October is ADHD Awareness Month October is ADHD Awareness Month, and CHADD is shining a spotlight on the critical importance of accurate diagnosis and effective treatment.
Cingulate_Logo_400x400_twitter.jpg
Cingulate’s Shane Schaffer Joins Cast of Nationally Syndicated Big Biz Show
08 oct. 2024 15h15 HE | Cingulate Inc.
KANSAS CITY, Kan., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Shane J. Schaffer, Chairman and CEO of Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed...